Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wenzhou Kangning Hospital Co., Ltd. (2120.HK)
HKD7.15
+0.04 (+0.56%)
CN HKSE Healthcare Medical - Care Facilities
Address
No.1 Shengjin Road
Wenzhou, CN
Wenzhou, CN
CEO
Weili Guan
Website
knhosp.cn
IPO
2015-11-20
ISIN CNE100002383
Description
Wenzhou Kangning Hospital Co., Ltd. oversees and manages a broad array of healthcare facilities throughout the People's Republic of China. A core part of its mission involves providing specialized psychiatric care. The company's diverse operations also encompass real estate rental and sales, software development and IT solutions, hospital administration, forensic analysis, general medical provisions, and the retail of pharmaceutical products. Established in 1996, the organization was initially known as Wenzhou City Kangning Psychiatric Rehabilitation Hospital before officially adopting its current name, Wenzhou Kangning Hospital Co., Ltd., in October 2014. Its principal offices are situated in Wenzhou, PRC.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
HKD7.15
+0.04 (+0.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4.7K
Beta
0.05
Float Shares
50.95M
Free Float %
72.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.00% | -1.11% | -1.66% | -7.19% | -18.94% | -8.25% | -2.20% | -26.45% | -67.04% | -78.40% | -81.87% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
7.15
DCF (Levered)
329.95
+4,514.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.85
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Care Facilities: +10.2%-2.1% Q4'25: +7.7% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-13.6% Q4'25: -55.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+4.2% Q4'25: +16.9% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+9.0% Q4'25: +10.4% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+4.0% Q4'25: +10.1% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%-3.1% ★ Q4'25: -4.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×5.13× Q4'25: 2.14× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
Dec 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
343.67M
est: 409.32M (-16.0%)
|
415.41M
est: 468.18M (-11.3%)
|
666.44M
est: 608.84M (+9.5%)
|
745.97M
est: 887.20M (-15.9%)
|
860.69M
est: 1.15B (-25.2%)
|
989.01M
est: 1.19B (-16.8%)
|
1.30B
est: 1.64B (-20.9%)
|
1.48B
est: 1.89B (-21.3%)
|
1.60B
est: 2.26B (-29.3%)
|
1.65B
est: 2.12B (-22.0%)
|
571.82M
571.82M – 571.82M
-73.0% YoY
|
833.26M
833.26M – 833.26M
+45.7% YoY
|
1.08B
1.08B – 1.08B
+29.8% YoY
|
1.12B
1.12B – 1.12B
+3.2% YoY
|
1.54B
1.54B – 1.54B
+38.1% YoY
|
1.77B
1.77B – 1.77B
+15.0% YoY
|
2.12B
2.12B – 2.12B
+19.7% YoY
|
| EBITDA |
95.41M
est: 57.10M (+67.1%)
|
115.01M
est: 123.39M (-6.8%)
|
104.56M
est: 119.78M (-12.7%)
|
160.12M
est: 96.36M (+66.2%)
|
155.79M
est: 138.77M (+12.3%)
|
189.39M
est: 99.06M (+91.2%)
|
194.76M
est: 97.76M (+99.2%)
|
174.97M
est: 263.25M (-33.5%)
|
252.67M
est: 119.42M (+111.6%)
|
131.89M
est: 274.62M (-52.0%)
|
74.03M
74.03M – 74.03M
-73.0% YoY
|
107.88M
107.88M – 107.88M
+45.7% YoY
|
139.99M
139.99M – 139.99M
+29.8% YoY
|
144.47M
144.47M – 144.47M
+3.2% YoY
|
199.56M
199.56M – 199.56M
+38.1% YoY
|
229.48M
229.48M – 229.48M
+15.0% YoY
|
274.62M
274.62M – 274.62M
+19.7% YoY
|
| EBIT |
74.17M
est: 32.61M (+127.5%)
|
97.88M
est: 84.22M (+16.2%)
|
78.23M
est: 110.79M (-29.4%)
|
121.27M
est: 99.28M (+22.2%)
|
80.24M
est: 130.43M (-38.5%)
|
101.13M
est: 60.89M (+66.1%)
|
131.96M
est: 60.09M (+119.6%)
|
60.75M
est: 150.35M (-59.6%)
|
139.12M
est: 73.41M (+89.5%)
|
109.70M
est: 192.20M (-42.9%)
|
51.81M
51.81M – 51.81M
-73.0% YoY
|
75.50M
75.50M – 75.50M
+45.7% YoY
|
97.97M
97.97M – 97.97M
+29.8% YoY
|
101.11M
101.11M – 101.11M
+3.2% YoY
|
139.66M
139.66M – 139.66M
+38.1% YoY
|
160.61M
160.61M – 160.61M
+15.0% YoY
|
192.20M
192.20M – 192.20M
+19.7% YoY
|
| Net Income |
55.71M
est: 57.84M (-3.7%)
|
68.83M
est: 68.17M (+1.0%)
|
49.07M
est: 86.41M (-43.2%)
|
80.60M
est: 66.51M (+21.2%)
|
38.23M
est: 99.39M (-61.5%)
|
55.77M
est: 76.09M (-26.7%)
|
44.04M
est: 75.09M (-41.4%)
|
-24.22M
est: 99.24M (-124.4%)
|
85.95M
est: 91.73M (-6.3%)
|
65.61M
est: 116.27M (-43.6%)
|
87.61M
87.61M – 87.61M
-24.6% YoY
|
84.77M
84.77M – 84.77M
-3.2% YoY
|
90.75M
90.75M – 90.75M
+7.1% YoY
|
79.56M
79.56M – 79.56M
-12.3% YoY
|
92.63M
92.63M – 92.63M
+16.4% YoY
|
102.82M
102.82M – 102.82M
+11.0% YoY
|
116.27M
116.27M – 116.27M
+13.1% YoY
|
| SGA |
64.49M
est: 24.85M (+159.5%)
|
81.68M
est: 78.91M (+3.5%)
|
93.51M
est: 96.54M (-3.1%)
|
103.14M
est: 138.16M (-25.3%)
|
131.32M
est: 150.24M (-12.6%)
|
133.13M
est: 213.27M (-37.6%)
|
51.75M
est: 210.47M (-75.4%)
|
74.30M
est: 242.52M (-69.4%)
|
68.56M
est: 257.11M (-73.3%)
|
59.70M
est: 273.02M (-78.1%)
|
23.14M
23.14M – 23.14M
-91.5% YoY
|
33.72M
33.72M – 33.72M
+45.7% YoY
|
43.75M
43.75M – 43.75M
+29.8% YoY
|
45.15M
45.15M – 45.15M
+3.2% YoY
|
62.37M
62.37M – 62.37M
+38.1% YoY
|
71.72M
71.72M – 71.72M
+15.0% YoY
|
85.83M
85.83M – 85.83M
+19.7% YoY
|
| EPS |
1.03
est: 0.78 (+32.3%)
|
0.94
est: 1.00 (-5.8%)
|
0.67
est: 1.09 (-38.7%)
|
1.10
est: 1.05 (+4.8%)
|
0.52
est: 1.18 (-56.0%)
|
0.77
est: 0.99 (-22.3%)
|
0.61
est: 1.12 (-45.5%)
|
-0.32
est: 1.34 (-124.0%)
|
1.15
est: 1.56 (-26.2%)
|
0.88
est: 1.62 (-45.5%)
|
1.22
1.22 – 1.22
-24.6% YoY
|
1.18
1.18 – 1.18
-3.2% YoY
|
1.26
1.26 – 1.26
+7.1% YoY
|
1.11
1.11 – 1.11
-12.3% YoY
|
1.29
1.29 – 1.29
+16.4% YoY
|
1.43
1.43 – 1.43
+11.0% YoY
|
1.62
1.62 – 1.62
+13.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
323.71M
OE per share TTM
4.48
Owner's Yield
51.02%
Maintenance CapEx ratio
211.88%
Maint CapEx / Avg PPE
86.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
30.0K
Shares Outstanding
70.40M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jian Wang | Vice GM, Joint Company Secretary & Executive Director | 989.8K | male |
| Lianyue Wang | GM & Executive Director | 954.2K | female |
| Weili Guan | Executive Chairman | 900.3K | male |
| Jin Hui | Chief Financial Officer | — | male |
| Ning Xu | Chairman of Supervisory Committee, President of Administration & President of Public Relations Dept. | — | male |
| Wai Chiu Wong | Joint Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2120.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
